Objective
to assess the clinical outcomes of the self-expanding ACURATE neo valve compared to the self-expanding CoreValve Evolut for treatment (TAVR) of severe aortic-stenosis
Study
multicentre, open-label, randomised non-inferiority trial (margin 6%)
Population
patients aged â¥75 years with symptomatic severe aortic stenosis and increased risk for surgical aortic valve mortality
Endpoints
composite of all-cause death or any stroke at 1 year
Conclusion
TAVR with the self-expanding ACURATE neo did not meet inferiority compared with the self-expanding CoreValve Evolut in terms of death and stroke at 1 year
Tamburino et al. Circulation. 2020;142:2431-42